Author Archives: Dr Richard Parry

G protein-coupled receptors (GPCRs) are a large family of proteins that play important roles in human health and disease. Roughly one third of all approved medicines work by targeting a GPCR however, historically none of these medicines have been monoclonal antibodies.

Congratulations to our University placement students Sofia, and Shannon who have passed their NCFE Level 2 Awards in Aseptic Services.

The road to effective treatments for Alzheimer’s disease has been littered with failures. However, clinical trials of lecanemab supported by Bath ASU have been heralded as a breakthrough -So what’s different this time?

The first monoclonal antibody to achieve marketing approval was Muromonab in 1986. Since then, monoclonal antibodies have become one of the most successful classes of current medicines bringing new therapies for cancer, immune diseases and a growing number of other indications.

Chronic migraine is a debilitating disorder that affects roughly one in fifty people globally with the cost to the National Health Service in the UK estimated to be £150 million each year.

The success of protein-based drugs has seen them impact on almost every branch of modern medicine. They are useful modulators of the immune system and this power has been applied in the clinic to devise new cancer therapies with stellar success. Sirukumab is an immune modulator that dampens inflammatory responses by binding the protein interleukin-6. This has already proved effective in treating rheumatoid arthritis, however, a more radical study is examining the usefulness of sirukumab in treating depression.